Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 477 Jan 1 – Oct 25, 2026
- Disclosed funding
- $20.2B 403 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| P Provides AI-powered commercial intelligence for Life Sciences organizations | $6M | Seed | Biotech | United States | Investors | |
| TB Think BioscienceCompany profile Develops small molecule drugs for historically challenging drug targets Develops small molecule drugs for historically challenging drug targets | $55M | Series A | Biotech | United States | Investors | |
| E ExcivaCompany profile Develops novel therapies for behavioral symptoms associated with Alzheimer's Disease Develops novel therapies for behavioral symptoms associated with Alzheimer's Disease | €51M | Series B | Biotech | Germany | Investors | |
| B BIOMAKERS analyzes clinical and genomic information. | $8M | Undisclosed | Biotech | United States | Investors | |
| C Cancilico develops AI diagnostic software for hematology. | €2.5M | Seed | Biotech, Healthtech | Germany | Investors | |
| AI Anzen IndustriesCompany profile Anzen Industries, now operating as Tera, develops modular cell-free enzyme reactors for manufacturing high-value chemicals. Anzen Industries, now operating as Tera, develops modular cell-free enzyme reactors for manufacturing high-value chemicals. | $2.2M | Pre-seed | Biotech | United States | Investors | |
| C Develops cell therapy platform for liver disease | $60M | Series A | Biotech | United States | Investors | |
| S SableCompany profile Develops high-performance topical solutions for body contouring and sustained aesthetic results Develops high-performance topical solutions for body contouring and sustained aesthetic results | Undisclosed | Pre-SeedPre-seed | Biotech | United States | Investors | |
| TM Transition Metal SolutionsCompany profile Develops custom chemical additives to enhance wild microbial communities for metal extraction Develops custom chemical additives to enhance wild microbial communities for metal extraction | $6M | Seed | Biotech, Industrial tech | United States | Investors | |
| CT Caldera TherapeuticsCompany profile Develops bispecific antibody CLD-423 for inflammatory bowel disease Develops bispecific antibody CLD-423 for inflammatory bowel disease | $37.5M | Series A1Series A | Biotech | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jan 1, 2026
- 1RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
23rounds3led - 2Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
15rounds1led - 3Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
15rounds0led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
14rounds0led - 5OrbiMed
Star Therapeutics, Leal Therapeutics, Accro Bioscience
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.